These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1978687)

  • 21. Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA.
    Huff AC; Ward RE; Kreuzer KN
    Mol Gen Genet; 1990 Mar; 221(1):27-32. PubMed ID: 2157956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteriophage T4 DNA topoisomerase is the target of antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in T4-infected Escherichia coli.
    Huff AC; Leatherwood JK; Kreuzer KN
    Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1307-11. PubMed ID: 2537494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
    Tan KB; Mattern MR; Eng WK; McCabe FL; Johnson RK
    J Natl Cancer Inst; 1989 Nov; 81(22):1732-5. PubMed ID: 2553992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells.
    Deffie AM; Bosman DJ; Goldenberg GJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):6879-82. PubMed ID: 2555055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
    Eijdems EW; de Haas M; Timmerman AJ; Van der Schans GP; Kamst E; de Nooij J; Astaldi Ricotti GC; Borst P; Baas F
    Br J Cancer; 1995 Jan; 71(1):40-7. PubMed ID: 7819046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circumvention of resistance by doxorubicin, but not by idarubicin, in a human leukemia cell line containing an intercalator-resistant form of topoisomerase II: evidence for a non-topoisomerase II-mediated mechanism of doxorubicin cytotoxicity.
    Zwelling LA; Bales E; Altschuler E; Mayes J
    Biochem Pharmacol; 1993 Jan; 45(2):516-20. PubMed ID: 8382067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase II as a target of antileukemic drugs.
    Zwelling LA; Estey E; Bakic M; Silberman L; Chan D
    NCI Monogr; 1987; (4):79-82. PubMed ID: 2819736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA).
    Bakic M; Beran M; Andersson BS; Silberman L; Estey E; Zwelling LA
    Biochem Biophys Res Commun; 1986 Jan; 134(2):638-45. PubMed ID: 3004458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
    Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
    Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
    Hong JH
    Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
    Harker WG; Slade DL; Drake FH; Parr RL
    Biochemistry; 1991 Oct; 30(41):9953-61. PubMed ID: 1655025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
    Patel S; Keller BA; Fisher LM
    Mol Pharmacol; 2000 Apr; 57(4):784-91. PubMed ID: 10727526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
    Bugg BY; Danks MK; Beck WT; Suttle DP
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
    Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F
    Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.